Navigation Links
Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression
Date:7/27/2009

SAN DIEGO, July 27 /PRNewswire/ -- BrainCells Inc., a company leading the scientific research of neurogenesis using its proprietary platform technology to identify novel pathways for the treatment of central nervous system (CNS) diseases, announced today results from the first clinical proof-of-concept study of BCI-952, a combination of low dose buspirone and melatonin, for the treatment of major depressive disorder (MDD). The data were presented at NCDEU 2009, a meeting co-sponsored by the National Institute of Mental Health and the American Society of Clinical Psychopharmacology. Neurogenesis is the process by which pre-existing stem cells in the hippocampus of the adult brain produce new brain cells, including neurons.

"Our study results provide the first prospective clinical validation of neurogenesis as a target for the treatment of mood disorders like depression, in contrast to the traditional focus on affecting serotonin function for antidepressant drug development," said lead investigator Maurizio Fava, M.D., vice chair, department of psychiatry at Massachusetts General Hospital and professor of psychiatry at Harvard Medical School. "Researchers have speculated that the brain's ability to grow new brain cells may have an impact on depression, and we now know that we can stimulate the natural process of neurogenesis with a positive clinical impact on depression symptoms."

"BCI-952 was selected by our proprietary platform for the compound's neurogenic properties," said Jim Schoeneck, chief executive officer of BrainCells Inc. "The platform was able to identify the pathway, ratio of drug and dosing that shaped the clinical trial protocol, directing the first rational approach to drug development in the area of psychiatry."

The double blind, placebo-controlled, randomized study evaluated the efficacy of BCI-952 for the treatment of MDD in 142 patients over a
'/>"/>

SOURCE BrainCells Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
2. Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
3. CareFirst BCBS Covers eNO Measurement for Diagnosis, Asthma Treatment
4. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
5. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
6. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
7. First Potential Lupus-Specific Treatment in Sight
8. New Research Shows: Neurofeedback is an Evidence-Based Treatment for ADHD
9. Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
10. Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer
11. ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., CARLSBAD,Calif.,Nov.24/PRNewswire-FirstCall/--Is...ntisensetherapeutics,todayannouncedthatmanagementw...alHealthCareConferenceonTuesday,December1,2009,at1...owebcastofthepresentationwillbeavailableonthe"Inve...isispharm.com .Areplayofthepresentationwillbeavail...
(Date:11/24/2009)..., SANDIEGO,Nov.24/PRNewswire-FirstCall/--OptimerPh...entatthe21stAnnualPiperJaffrayHealthCareConference...:00p.m.EasternTime. ,, (Logo: http://www.newsco...iveaudiowebcastofthispresentationwillbeaccessibleo...merpharma.com .Replaysofthispresentationwillbeava...
(Date:11/24/2009)..., NEWYORK,Nov.24/PRNewswire-FirstCall/--KeryxBioph...tRonBentsur,theCompany,sChiefExecutiveOfficer,issc...areConferencebeingheldinNewYorkCity. ,, Mr.Bent...mber2ndat10:30AMETandwillbeaccessiblefromtheInvest...vestors.keryx.com .Anarchivedversionofthewebcastwi...
Breaking Medicine Technology:Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2NovaMin Technology Inc Welcomes New Board Member 14112 1NovaMin Technology Inc Welcomes New Board Member 14112 2Teamsters Oppose Baucus Plan to Tax Health Insurance Companies 57442 1Teamsters Oppose Baucus Plan to Tax Health Insurance Companies 57442 2Baucus Bill Imposes Additional Tax Burdens on Nonprofit Hospitals 57437 1Baucus Bill Imposes Additional Tax Burdens on Nonprofit Hospitals 57437 2
...n Cohort 3 Demonstrated Improvement in T-Cell Resp...otential of HspE7, SAN DIEGO, May 12 Nventa Biop...ced positive immunological data from the,third coh...ead product,candidate, HspE7, in patients with cer...or to cervical cancer. HPV 16 E7-specific T-cell r...
...icine Studied in Patients Following Bunionectomy,...xperience intense pain for several days following ...urgeries. The investigational pain,medication tape...o had this,surgery, compared to those treated with...in patients reporting fewer gastrointestinal side ...
Other Medicine Technology:Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 3Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 4Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 5Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 6New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 2New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 3New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 4New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 5
(Date:11/24/2009)...re-USNewswire/--Dr.NelsonEscobar,aphysicianwiththe...eJamesBradyAward.TheawardwaspresentedtohimbytheBra...lconferenceonOctober30,2009. ,, AccordingtotheB...onofhisexpertiseinaddressingthecomplexneedsofperso...ceptionalcareofhispatientsandtheirfamiliesastheyre...
(Date:11/24/2009)...ard off peripheral artery disease, researchers sa...-- Among people aged 75 and older, the herbal supp...s, stroke or death, a new study finds. , There ...ght help prevent the leg-circulation problem known...o contains nutrients called flavonoids, which are ...
(Date:11/24/2009)...nd that hormones produced during pregnancy induce ...ast cancer. This protein, alpha-fetoprotein (AFP),...he treatment and prevention of breast cancer, acco...Research , a journal of the American Association f...uch as estrogen, all induce AFP, which directly in...
(Date:11/24/2009)...Newswire/--Thereisanewgameintownwhenitcomestodeali...agmaticandrealisticstrategieswheretraditionalappro...ovementisagroupcalledHAMS--HarmReduction,AlcoholAb...,lay-ledsupportandinformationalgroupforpeoplewhodr...seandAlcoholismtellsusthatonly7%ofpeoplewithanalco...
(Date:11/24/2009)...re/--Thankstoaninnovativeprogramrecentlydevelopedb...BlueCrossandBlueShieldinMaine,someAnthemmembersinB...outleavinghome. ,, Aspartofthepilot,Anthemmembe...dcommunicateviaemailwiththeirprovideraboutnon-emer...kingontestresults,orrequestingprescriptionrefills....
Breaking Medicine News(10 mins):Health News:Marianjoy Medical Group Physician Receives James Brady Award 2Health News:Ginkgo Won't Prevent Heart Attack, Stroke in Elderly 2Health News:Ginkgo Won't Prevent Heart Attack, Stroke in Elderly 3Health News:Protein from pregnancy hormone may prevent breast cancer 2Health News:Harm Reduction for Alcohol: An Idea Whose Time Has Arrived 2Health News:The Doctor Will See You Now. . .Online 2
... drugs heighten suicide risk, and they recommend m...July 10 (HealthDay News) -- Anti-seizure drugs ca... but not enough to warrant the government,s strong... findings on 11 antiepileptic drugs studied by the...
...with a tip the size of a needle, Stanford research... muscles in live humans, with minimum discomfort t...lcome. , This microendoscopy technique for viewin...n which a portion of the muscle is removed for exa...
...seizure drugs that showed double the risk , ...izure drugs can cause increased suicidal tendencie...ded Thursday. , The 20-member panel of experts vot...late January, the FDA announced an agency review ...
...cago and Los Angeles Life Time Fitness ...uly 10 MGD 64 today announced it will,sponsor thr...s Race to the,Toyota Cup events: the July 12 Life ...exclusive beer sponsor of the events, MGD 64 will ...
... restaurant during the breakfast rush the clang o...ces was the crucial test of new hearing aid techn...ngton University School of Medicine in St. Louis. ...devices didn,t need to fly from St. Louis to Chica...
...rther Positions the Company as a Weight Loss ...if., July 10 Jenny Craig, Inc. is pleased,to anno... for the worldwide,rights to use the Volumetrics(R... author of the New York Times,bestselling books Th...
Other Medicine News:Health News:FDA Advisers Don't Back Epilepsy Drug Warnings 2Health News:Stanford Bio-X researchers use needle-thin probe to get first look at working muscle fiber 2Health News:Epilepsy Drugs Can Cause Suicidal Tendencies, FDA Panel Finds 2Health News:Epilepsy Drugs Can Cause Suicidal Tendencies, FDA Panel Finds 3Health News:MGD 64 to Sponsor National Triathlons 2Health News:MGD 64 to Sponsor National Triathlons 3Health News:New hearing aid technology passes the restaurant noise test 2Health News:New hearing aid technology passes the restaurant noise test 3Health News:Jenny Craig Establishes License Agreement for Volumetrics(R) 2Health News:Jenny Craig Establishes License Agreement for Volumetrics(R) 3
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
Medicine Products: